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Cord blood transplantation (CBT) is curative for many primary immunodeﬁciencies (PIDs) but is associated
with risks of viral infection and graft-versus-host disease (GvHD). Serotherapy reduces GvHD but potentially
increases the risk of viral infection by delaying immune reconstitution. Because many PID patients have pre-
existing viral infections, the optimal dose of serotherapy is unclear. We performed a retrospective analysis in
34 consecutive PID patients undergoing CBT and compared immune reconstitution, viral infection, GvHD,
mortality, and long-term immune function between high-dose (n ¼ 11) and low-dose (n ¼ 9) serotherapy.
Serotherapy dose had no effect on neutrophil engraftment. Median CD3þ engraftment occurred at 92.5 and
97 days for high- and low-dose serotherapy, respectively. The low-dose serotherapy group had higher CD3þ,
CD4þ, and early thymic emigrant counts at 4 months compared with the high-dose group. GvHD severity and
number of viral infections did not differ between serotherapy doses. Survival from the transplantation process
was 90.9% for high-dose and 100% for low-dose groups. In conclusion, low-dose serotherapy enhanced T cell
reconstitution and thymopoiesis during the ﬁrst year after CBT with no increase in GvHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Primary immunodeﬁciencies (PIDs) are inherited condi-
tions characterized by recurrent infections, inﬂammatory
disorders, and autoimmunity. Severe combined immunode-
ﬁciency (SCID), the most severe form of PID, is usually fatal
within the ﬁrst year of life unless corrected [1]. Other T cell
and innate immune defects have excessive morbidity and
mortality through childhood and early adulthood. Hemato-
poietic stem cell transplantation (HSCT) is curative for many
patients with a 10-year survival of 84% in HLA-matched
sibling HSCT for SCID [2,3]. Ten-year survival for non-SCID
PID is 71% for HLA-matched sibling HSCT, with survival
rates improving over time [2,3].
Umbilical cord blood offers an alternative source of stem
cells for transplantation (cord blood transplantation, CBT)
when a matched sibling donor is unavailable. Advantages
and disadvantages of CBT over bone marrow transplantation
(BMT) and peripheral blood stem cells (PBSC) are reviewed in
detail elsewhere [4,5]. Advantages include (1) easy access to
the cord blood unit and, therefore, earlier transplantation;
(2) absence of risk to donor; (3) lower risk of latent viral
transmission and graft-versus-host disease (GvHD); and (4)
higher chance of matching rare HLA haplotypes. However,
the stem cell dose is often low and unrelated donors are not
available for boost HSCT. Cord blood units are virologically
naïve and often show slower engraftment due to a lowerdgments on page 248.
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13.11.005CD34þ dose compared to BMT and PBSCs. Both of these
factors increase the risks from pre-existing infections in CBT
for PID patients.
Evidence for the effectiveness of CBT in PID comes from a
few single center and multicenter studies [6-10]. A recent
study demonstrated a lower rate of grades II to IV GvHD and
improved survival in unrelated CBT when the authors
compared their results with similar studies of BMT for PID
and that mortality was associated with pre-existing infec-
tion, no conditioning, 2 HLA mismatch and underlying
disease [10]. However, this study does not provide data on
lymphocyte reconstitution or long-term graft function. Other
studies with limited data on lymphocyte reconstitution show
that absolute lymphocyte counts increase from 2 months
with a proportional increase in CD4þ and CD8þ T cells from
3 months post CBT and that age-related normal values for
CD19þ, CD3þ, and CD4þ are reached by 24 months in all
patients studied [7,11]. All surviving patients in 1 series were
independent of intravenous immunoglobulin and responded
to T cell stimulation, tetanus, and hepatitis B vaccination [7].
Serotherapy in the form alemtuzumab (T and B cell
depleting anti-CD52 humanized monoclonal antibody) is
added to conditioning regimens to reduce the incidence of
GvHD [12-16]. Immune reconstitution is delayed by alem-
tuzumab in patients with malignant and nonmalignant
hematological conditions [13,16,17] with some studies sug-
gesting slower immune reconstitution with higher doses
used [12,18]. This slower immune reconstitution is, in turn,
associated with an increased incidence of viral reactivation,
notably cytomegalovirus [17, 20-22], adenovirus [14,23,24]
and respiratory viruses [25]. This is particularly pertinent
when considering CBT for PID because many patients haveTransplantation.
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considered to have slower immune reconstitution and be
virologically naïve [4,5]. The role of serotherapy in CBT for
PID has not been explored to date.
We report the results of a retrospective study of the ef-
fects of 2 alemtuzumab-based serotherapy dose regimens on
lymphocyte reconstitution, GvHD, viral infection, and mor-
tality in PID patients who underwent CBT at an international
center.
MATERIALS AND METHODS
Patients and Exclusion Criteria
Thirty-four consecutive patients who underwent CBT for PID between
May 1999 and December 2010 at the Children’s BMT Unit, Newcastle upon
Tyne Hospitals NHS Foundation Trust, United Kingdomwere identiﬁed from
the unit’s database. A retrospective study of these patients was performed,
of which 14 have been previously reported [6]. There was a systematic
change in serotherapy policy at the Children’s BMT Unit in 2006 to 2007,
when the alemtuzumab dose was reduced to determine if it had the same
protective effects on GvHD without an increase in viral infection. Two pa-
tients were excluded from further analysis because they received alemtu-
zumab before conditioning at 3 and 4 weeks before CBT, and another was
excluded because the patient received rabbit antithymocyte globulin (ATG)
instead of alemtuzumb. Those who received no serotherapy (n ¼ 11) were
also excluded because 6 did not receive chemotherapeutic conditioning and
others were selected to this group based on clinical presentation. The
remaining patients were retrospectively nonrandomly assigned to high-
dose (alemtuzumab  .9 mg/kg given in 5 divided doses before day -10 or
between day -8 and day -4; n¼ 11) or low-dose (alemtuzumab .3 to .6mg/kg
given in 3 divided doses on consecutive days between day -11 and day -6;
n ¼ 9) serotherapy groups for the purpose of analysis. No alemtuzumab
pharmacokinetic studies were performed. Underlying diagnoses by sero-
theraphy group are shown in Supplementary Table S1.
Umbilical Cord Transplantation Procedure
Search for a suitable umbilical cord donor unit was initiated if a matched
sibling cord was stored or if a matched sibling donor was unavailable.
Transplantation characteristics are summarized in Table 1. HLA matching
was based on low-resolution molecular class I and high-resolution molec-
ular class II typing at 10 HLA loci as previously described [6]. Patients were
conditioned according to the European Blood and Bone Marrow TransplantTable 1
Patient and Donor Cord Blood Unit Characteristics with Respect to
Serotherapy Dose
Serotherapy Dose P Value
High Low
No. of patients 11 9
Year of CBT .001
1999-2005 8 0
2006-2010 3 9
Age at CBT, median
(range), wk
26 (8-51) 24 (7-52) .790
Underlying diagnosis* 1.00
SCID 5 5
Non-SCID 6 4
Cord unit source 1.00
MUD 5 5
MMUD 6 4
HLA match .496
10/10 5 5
9/10 6 3
8/10 0 1
Nucleated cell dose, median
(range),  108/kg
1.1 (.36-3.10) 1.3 (.55-3.8) .648
CD34þ cell dose, median
(range),  106/kg
.29 (.067-1.45) .63 (0.15-1.90) .239
Chemotherapy conditioning .406
Myeloablative 6 3
RIC 5 6
CBT indicates cord blood transplant; SCID, severe combined immunodeﬁ-
ciency; MSD, matched sibling donor; MUD, matched unrelated donor;
MMUD, mismatched unrelated donor; RIC, reduced-intensity conditioning.
* Further details of diagnoses are available in Supplementary Table S1.Group (EBMT) guidelines, EBMT Working Party for Inborn Errors, and
clinical condition, and they received either myeloablative conditioning
(busulphan 16 mg/kg þ cyclophosphamide 200 mg/kg or treosulphan
36 g/m2 þ cyclophosphamide 200 mg/kg; n ¼ 9) or reduced-intensity
conditioning (treosulphan 36 g/m2 þ ﬂudarabine 150 mg/m2 or ﬂudar-
abine 150 mg/m2 þ melphalan 140 mg/m2; n ¼ 11). Patients also received
either high-dose or low-dose serotherapy as part of their conditioning
regimen allocated as described above. The cord blood unit was transfused on
day 0 with a median nucleated cell count of 1.30  108 cells/kg (range, .36 to
3.8) and a median CD34þ count of 3.70  105 cells/kg (range, .67 to 19.0).
Supportive Measures and Prophylaxis
All patients were nursed in HEPA-ﬁltered cubicles. Patients received
cyclosporine for GvHD prophylaxis, cotrimoxazole for Pneumocystis jiroveci
prophylaxis, liposomal amphotericin for antifungal prophylaxis, and aci-
clovir for antiviral prophylaxis. Patients received blood and platelet support
and granulocyte colony stimulating factor until engraftment, at the discre-
tion of the managing physician. All parents gave written consent according
to our local centre and European Blood and Marrow transplantation
guidelines.
Immunological Studies
Time to neutrophil (third consecutive day of absolute neutrophil count
(ANC) > .5  109/L), platelet (platelet count of >50  109/L independent of
transfusion support) and T lymphocyte (ﬁrst day of a CD3þ count > 200
cells/mL) engraftment was recorded. Lymphocyte subset analysis was
measured by 4-color ﬂow cytometry as previously described [26]. Brieﬂy,
lymphocyte surface marker studies were performed on fresh whole blood
collected in EDTA using appropriate markers (CD45 PerCP, CD3 FITC, CD4
APC, CD8 PE, CD19 APC, CD16/CD56 PE, CD3 PerCP/CD4 APC/CD45RAFITC/
CD27 PE, CD19 PerCP/CD27 FITC/IgM APC/IgD PE [Becton Dickinson, UK Ltd,
Oxford]), and analyzed on a Becton Dickinson FACS Calibur ﬂow cytometer.
The markers CD4þ/CD45RAþ and CD4þ/CD45RAþ/CD27þ were used as sur-
rogates for early thymic emigrant equivalents (ETEEs) [27]. Lymphocyte
subsets (CD3þ, CD4þ, CD8þ, CD19þ, natural killer [NK] cells and CD4þ ETEEs)
at 2, 4, 6, and 12 months follow-up were recorded. Speciﬁc antibody re-
sponses to pneumococcal (polysaccharide or Prevenar), tetanus toxoid and
Haemophilus inﬂuenzae b vaccine antigens were measured by ELISA and
deﬁned as present or absent after vaccination [28].
Chimerism Studies
Whole blood was stained with CD3, CD19, or CD15 micro beads and cell
lines were separated using an autoMACS automated bench-top magnetic
cell sorter (Miltenyi Biotec Ltd, Surrey, UK). Chimerismwasmeasured in sex-
mismatched cases by XY-ﬂuorescent in-situ hybridization (FISH) using
standard cytogenetic techniques. Brieﬂy, interphase FISH was performed
using a Vysis 2-color CEP X/CEP Y probe set according to the manufacturer’s
protocol. Where donor and recipient were same sex, chimerism was
measured by short tandem repeat marker analysis of genomic DNA, as
previously described [29]. Most recent donor chimerism for T cell, B cell, and
myeloid lineages was recorded. Chimerism was deﬁned as donor (>95%
donor cells), high-level mixed (50% to 95% donor cells), mixed (5% to 49%
donor cells) or recipient (<5% donor cells) in speciﬁc cell lineages.
Viral Clearance
Patients were considered to have viral infectionwhen a positive virology
result by PCR, tissue culture, electron microscopy, or immuno-chromogenic
methods was present. Viral PCR for adenovirus, cytomegalovirus, human
herpes virus 6, Epstein-Barr virus, enterovirus, parainﬂuenza virus 3, res-
piratory syncytial virus, coronavirus, astrovirus, varicella-zoster virus, and
norovirus; electron microscopy for small round structured virus, coronavi-
rus, norovirus, astrovirus, and rotavirus; tissue culture for poliovirus vaccine
strains; and immuno-chromogenic methods for adenovirus and rotavirus
were undertaken at Newcastle Health Protection Agency Laboratories,
Newcastle, United Kingdom. Viral infections were considered cleared on the
ﬁrst of 3 consecutively negative virology results. If there was recurrence of
the same infection at a later date, this was treated as failure to clear the
virus. Viral infection was considered present if the patient died with most
recent result being positive or if there was still virological evidence of
infection at last follow-up.
GvHD, Mortality and Follow-up
GvHD grade, target organ, and whether it was acute or chronic were
recorded. GvHD was deﬁned by modiﬁed Glucksberg criteria. Time to death
and cause of death were recorded. Transplantation-related mortality (TRM)
was deﬁned as cause of death as a direct result of the transplantation pro-
cedure. Time to most recent follow-up and independence of replacement
immunoglobulin were recorded.
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Differences between high- and low-dose serotherapy were analyzed.
Fisher’s exact and Mann-Whitney U tests were performed using SAS 9.2 for
Windows (SAS Institute Inc., Cary, NC). Kaplan-Meier survival analysis, 95%
conﬁdence intervals, and log-rank test were performed using SPSS Statistics
19 (IBM SPSS, Armonk, NY). All tests were considered statistically signiﬁcant
if P < .05.
RESULTS
Transplantation Characteristics and Serotherapy Dose
Demographics and transplantation characteristics are
summarized in Table 1. All patients were 12 months of age or
younger at transplantation. Only year of transplantation was
signiﬁcantly different between high-dose and low-dose
serotherapy groups (P ¼ .001). Low-dose serotherapy CBT
all occurred after 2006, whereas high-dose serotherapy CBT
mainly occurred before 2006, consistent with the systematic
change in practice.
Engraftment
Neutrophil engraftment was similar for high- and low-
dose serotherapy (P ¼ .675), with median engraftment
occurring at 21 days (range, 13 to 38) and 20 days (range, 15
to 31), respectively. Platelet engraftment occurred at a me-
dian of 38 days (range, 18 to 114) and 31 days (range, 0 to 46)
for the high- and low-dose serotherapy groups respectively
(P ¼ .095). Platelet engraftment took over 100 days in 1 pa-
tient in the high-dose serotherapy group.
Lymphocyte Reconstitution
CD3þ lymphocyte engraftment occurred at a median time
of 92.5 days (range, 56 to 222) and 97 days (range, 14 to 107)
for high- and low-dose serotherapy, respectively (P ¼ .171).
T lymphocyte counts increased throughout the ﬁrst
12 months post CBT across the different T lymphocyte sub-
sets (Table 2, Figure 1A-D). Reconstitution was similar at
2 months for high- and low-dose serotherapy groups for all
T lymphocyte subsets. At 4 months the low-dose serotherapy
group had signiﬁcantly higher CD3þ, CD4þ, and CD4þ ETEE
counts, as compared with the high- dose group (P ¼ .037, P ¼
.037 and P ¼ .021 respectively). CD4þ ETEE reconstitution
followed a similar trend to CD4þ reconstitution (Figure 1D).Table 2
Median Lymphocyte Counts by Month and Serotherapy Group
Lymphocyte Subset Serotherapy Dose Lymphocyte Count, Med
2 Months
CD3þ High 48 (0-515)
Low 146 (0-638)
P value .614
CD4þ High 20 (0-382)
Low 0 (0-519)
P value .685
CD8þ High 46 (0-320)
Low 0 (0-141)
P value .403
CD4þ ETEE High Not measured
Low Not measured
P value NA
CD19þ High 415 (0-2323)
Low 1143 (405-6833)
P value .119
NK cells High 357 (184-771)
Low 226 (136-363)
P value .006
Mann-Whitney U P values stated for difference between high- and low-dose serotBy 6 and 12 months, CD3þ, CD4þ, and CD4þ ETEE cell
reconstitution in the high-dose group was similar to low-
dose group. CD8þ lymphocyte reconstitution was similar
for high- and low-dose serotherapy groups throughout the
ﬁrst 12 months after CBT.
B lymphocyte counts showed a trend of increasing in
number over the ﬁrst 12 months post CBT for both high- and
low-dose serotherapy. There was no signiﬁcant difference in
B cell reconstitution between high- and low-dose serother-
apy groups (Table 2, Figure 1E). NK cell counts were sig-
niﬁcantly higher at 2 months (P ¼ .006) for high-dose
serotherapy as compared with low-dose serotherapy. At 4,
6, and 12 months, there was no signiﬁcant difference in NK
cell counts between serotherapy groups (Table 2, Figure 1F).
Viral Clearance
Seven patients had at least 1 viral infection at time of CBT
and 7 patients contracted at least 1 viral infection post
transplantation. Of these, 9 patients achieved clearance of all
virus and a further 3 patients had insufﬁcient data to deter-
mine achievement of viral clearance. There was no difference
in the number of viral infections present at CBT or new viral
infection after CBT between high- and low-dose serotherapy
groups. All evaluable patients who received serotherapy
cleared viral infections (Table 3). There were insufﬁcient
results to analyze the time to viral clearance further.
Chimerism and Graft Function
There was no signiﬁcant difference in donor chimerism
between high-dose and low-dose serotherapy in any of the
3 cell lineages (Figure 2). One patient with Chronic Granu-
lomatous Disease who received high-dose serotherapy has
undergone a second HSCT for falling myeloid chimerism.
All except 2 patients discontinued replacement immu-
noglobulin by 24 months and all those who have been
vaccinated have responded to Haemophilus inﬂuenza b,
tetanus toxoid, and pneumococcal vaccinations (Table 3).
Two patients who received high-dose serotherapy were
dependent on immunoglobulin therapy to 32 and 34 months
and have since made a good response to primary vaccina-
tions. One patient in the low-dose serotherapy group hasian (range) in Cells/mL
4 Months 6 Months 12 Months
555 (0-1339) 1423.5 (82-3774) 3423 (158-7045)
1103 (176-1694) 1871 (203-4201) 3477 (1587-5952)
.037 .462 .508
248 (0-1123) 746.5 (48-2711) 2139 (123-6077)
747 (119-1243) 1515 (176-2232) 2754 (923-4033)
.037 .288 .085
143 (0-308) 304.5 (27-2821) 1071 (29-2813)
179 (0-467) 357 (49-759) 996 (415-1750)
.569 .462 .965
31.5 (0-455) 318.5 (0-1691) 1614 (0-4862)
339 (13-677) 724 (23-1318) 1786 (556-2619)
.021 .286 .270
1320 (0-4517) 1473 (32-3355) 1475 (577-2155)
1445 (650-2630) 1286 (278-2294) 1840 (0-2410)
.382 1.00 .310
485 (167-1399) 434.5 (32-1547) 288 (163-1277)
346 (93-489) 382 (125-1562) 417 (202-787)
.113 .514 .627
herapy and considered signiﬁcant if P < .05.
Figure 1. Immune reconstitution over the ﬁrst 12 months after CBT showing median cell counts/mL for (A) CD3þ, (B) CD4þ, (C) CD8þ, (D) CD4þ early thymic emigrant
equivalents (ETEEs) (E) CD19þ, and (F) NK cells. P values given where Mann-Whitney U test showed a signiﬁcant difference in cell counts between serotherapy doses.
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primary vaccinations.
GvHD and Mortality
Eight patients developed acute GvHD (40%); 5 grade II
GvHD (25%). No patients experienced grade IV GvHD. There
was no statistically signiﬁcant difference in the severity of
GvHD between high- and low-dose serotherapy groups (P ¼
.464; Table 3). One patient, who received high-dose sero-
therapy, developed chronic skin GvHD.
All TRM occurredwithin 6months of transplantation. One
patient who received high-dose chemotherapy died from
TRM (possible veno-occlusive disease and gastrointestinal
hemorrhage complicated by chronic lung disease). Another
patient who received high-dose serotherapy died from sud-
den infant death syndrome and was not classiﬁed as TRM.
Cumulative survival from TRM in high-dose and low-dose
serotherapy groups was 90.9% (95% conﬁdence interval,
50.8% to 98.7%) and 100%, respectively, with no difference in
survival between groups (P ¼ .366; Figure 3).DISCUSSION
NK and B cell reconstitution has been demonstrated to
occur early after CBT, whereas low T cell numbers have been
demonstrated to remain for the ﬁrst 6 months post CBT
[11,30], increasing the potential risk of viral infections as
compared to BMT or PBSC [4,5]. Giving T lymphocytee
depleting serotherapy as GvHD prophylaxis prolongs
T lymphopenia post transplantation [12,18] and giving
high doses can increase the risk of viral infection further
[14,17,20-25]. In our study, lower dose serotherapy improved
T lymphocyte reconstitution with better thymopoiesis at
4 months post transplant than high-dose serotherapy. This is
particularly pertinent in the setting of CBT for PID. In our
study, the majority of patients had SCID and, therefore,
further delay in T cell reconstitution from excessive sero-
therapy might delay clearance of pre-existing viral infection.
The delay in immune reconstitution between high- and low-
dose serotherapy could be explained by the prolonged
exposure of the graft to lympholytic antibodies when higher
doses are given. Lympholytic concentrations of alemtuzumab
Table 3
Transplantation Outcomes and Complications after Cord Blood
Transplantation
Serotherapy P Value
High Dose Low Dose
Viral infection
No. patients with pre-existing
infection at CBT
.404
No virus 6 8
1 viral infection 3 1
2 þ viral infection 2 0
No. patients with new infection
post CBT
.336
No virus 8 5
1 viral infection 3 2
2 þ viral infections 0 2
Viral clearance NA
No. patients achieving complete
viral clearance
5 4
No. patients not clearing all virus 0 0
Acute GvHD .464
0 6 6
I 1 2
II 4 1
III 0 0
Immunoglobulin replacement
stopped by 24 months
7/9 9/9 NA
Achieved vaccine response 9/9 8/8 NA
Mortality 1 TRM þ
1 SIDS
0
Transplantation survival rate .909 1.00 .366
CBT indicates cord blood transplantation; GvHD, graft-versus-host disease;
TRM, transplantation-relatedmortality; SIDS, sudden infant death syndrome.
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when very high doses are given in vivo [31].
A recent prospective series of 30 pediatric patients who
underwent CBT for malignant and nonmalignant disease
without serotherapy conditioning showed early restoration
of T lymphocytes within the ﬁrst 2 months post CBT from a
thymic independent pathway that produced effective viral
speciﬁc T cells. Thymopoiesis was evident at 1 year after
transplantation [32]. In contrast to this study by Chiesa et al.,Figure 2. Most recent chimerism results for (A) T cell, (B) B cell, and (C) myeloid cell li
between high and low-dose serotherapy for any of cell lineage ((A) P ¼ .566, (B) P ¼our study demonstrated a delayed restoration of median T
cell counts until 4 months post CBT when low-dose sero-
therapy was given and a further delay in T lymphocyte
reconstitution to 6 months post CBT when using high dose
serotherapy. CD3þ reconstitution in our study improved at
4 months when low-dose serotherapy was given as com-
pared with high-dose serotherapy, which is likely caused by
corresponding improvements in CD4þ and CD4þ ETEE counts
in the low-dose serotherapy group. The evidence of thymo-
poiesis in the low-dose serotherapy group at 4 months again
contrasts with the study by Chiesa et al. The T cell reconsti-
tution in the low-dose serotherapy group seen in our study at
4 months post transplantation is, therefore, likely to be
explained by expansion in both a thymic dependant and
independent manner.
Patients in our study experienced much lower rates of
acute GvHD than in the study by Chiesa et al. (grade II to IV
acute GvHD 25% versus 50%), though this may have been
confounded by the inclusion of patients with malignant
disease in the latter study [32]. We found the protection
afforded against GvHD by lower dose serotherapy to be
similar to high-dose serotherapy. In the study by Chiesa et al.,
63% of patients had viral infections and 2 patients died from
viral infection [32]. In our study, 35% of patients had
pre-existing viral infection, and 35% developed new viral
infection after CBT, with no difference between high- and
low-dose serotherapy groups. This is important in the PID
setting where many patients present with pre-existing viral
illness. However, our deﬁnition of viral clearance and the
small numbers of patients with viral infection at time of
transplantation make it difﬁcult to determine the effects of
serotherapy dose on clearance of pre-existing viral in-
fections. The inﬂuence of giving serotherapy on viral clear-
ance in the context of PID and CBT needs further work with
larger studies.
Other single and multicenter studies of CBT for PID ten-
ded to use a standard dose of ATG as serotherapy [7-10].
Knutsen et al. demonstrated that in 8 patients with T cell
immunodeﬁciencies who received the same dose of ATG
(30 mg/kg/day for 3 days) CD4þ and CD8þ lymphocyteneages for high- and low-dose serotherapy. There was no signiﬁcant difference
.816, (C) P ¼ .910).
Figure 3. Kaplan-Meier survival curves representing survival from
transplantation-related mortality for high dose (.909, 95% conﬁdence interval
.508-.987) and low-dose serotherapy (1.00). There was no difference in sur-
vival between high dose and low-dose serotherapy groups (P ¼ .366).
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thymopoiesis (using presence of CD4þ/CD45RAþ cells as
marker) from 12 to 24 months [9]. This evidence of thymo-
poiesis occurs later than that demonstrated by the low-dose
serotherapy group in our study. Overall other studies
demonstrated higher rates of GvHD grades II to IV than our
study [7-10]. However, these rates of GvHD aremore likely to
be caused by the greater number of CBT with 2 or more
mismatched HLA loci, as compared with our study than the
difference in serotherapy used. This, combined with the use
of ATG rather than alemtuzumab, makes a direct comparison
to our study difﬁcult.
There are currently limited data regarding T cell function
post CBT. Proliferative responses to mitogens and viral-
speciﬁc T cell function have been demonstrated as early as
2 months post CBT [9,30,32]. The T cell receptor repertoire
has been shown to have a skewed distribution at 1 year post
CBT but increased diversity as comparedwith BMT recipients
at 2 years post HSCT [33]. Our current study shows that
clinically there is good long-term immune function with
independence from immunoglobulin replacement by 2 years
post CBT and response to primary vaccinations independent
of serotherapy dose. Our study is, however, limited to looking
at numerical and not functional immune reconstitution and
analysis of the effects of serotherapy on T cell functional
reconstitution merits further work.
Our study is limited to comparing high- and low-dose
serotherapy regimens only and no comparison was made
to patients not receiving serotherapy as part of their condi-
tioning regimen. This is because patients who did not receive
serotherapy were preselected based on poor clinical condi-
tion at time of transplantation, many of whom did not
receive chemotherapeutic conditioning either, or they did
not receive serotherapy because they received a matched
sibling donor CBT. The only factor that differed signiﬁcantly
between the high and low-dose serotherapy groups was thatlow-dose serotherapy CBT occurred more recently. This was
due to a systematic change in the serotherapy policy at our
unit. This would have allowed for introduction of more up-
to-date supportive measures in the low-dose serotherapy
group, potentially inﬂuencing survival but not immune
reconstitution.
Our results show that low-dose serotherapy improves
speed of immune reconstitution and thymopoiesis over the
ﬁrst year after CBT without an increase in incidence of GvHD,
as compared with high dose serotherapy. Our results also
demonstrate lower rates of GvHD than in other studies. The
extent that giving serotherapy affects the risk of delayed viral
clearance is unclear from the current study and further
research is needed.
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